{"id":"pacmx5","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PACMx5 is an individualized therapeutic cancer vaccine that combines personalized neoantigen identification with checkpoint inhibitor therapy. The vaccine is engineered based on each patient's unique tumor mutations to generate a targeted immune response against cancer cells. It is being evaluated in combination with standard chemotherapy and immunotherapy in phase 3 trials.","oneSentence":"PACMx5 is a personalized neoantigen vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:25:32.198Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer (in combination with chemotherapy and immunotherapy)"}]},"trialDetails":[{"nctId":"NCT01061437","phase":"PHASE3","title":"S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-06","conditions":"Helicobacter Pylori Infection","enrollment":1859}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lansoprazole: Prevacid"],"phase":"phase_3","status":"active","brandName":"PACMx5","genericName":"PACMx5","companyName":"SWOG Cancer Research Network","companyId":"swog-cancer-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PACMx5 is a personalized neoantigen vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations. Used for Pancreatic cancer (in combination with chemotherapy and immunotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}